Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids & Tox Screening Europe 2019

Abstract



Organoids, A Preclinical Patient Population

Robert Vries, CEO, Hubrecht Organoid Technology (HUB)

Key to the improvement of drug development and disease modeling is a preclinical model that represents patients. We previously developed an adult stem cells derived culture system that allowed for the genetically and phenotypically stable expansion of human epithelial cells. The Organoids derived from a variety of organs such as lung, liver, pancreas, breast, etc, are a powerful tool to study Cancer, Cystic Fibrosis and other diseases. Recent studies show that the in vitro response to drug treatments tested organoids correlate with the clinical outcome of the patient from which the organoid was derived.  Therefore, the organoids appear to faithfully represent a patient in the lab.  The scalability of the organoids potentially provides a novel approach to screening in early discovery, drug development as well as predictive diagnostics.


Add to Calendar ▼2019-06-13 00:00:002019-06-14 00:00:00Europe/London3D-Culture, Organoids and Tox Screening Europe 20193D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com